Back to search
FDAFDA · Food and drugs·Recall number D-1047-2019

Valsartan Tablets USP 160 mg, 100 Tablets (10 x 10) per Unit Dose Blisters, Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217 (Individual Dose NDC:60687-139-11, Carton NDC#: 60687-139-01)

Published March 27, 2019 · Recall initiated: March 6, 2019

Summary

FDA records drug Class II recall D-1047-2019, published March 27, 2019 and initiated March 6, 2019. Recalling firm: American Health Packaging; Status: Terminated; Reported quantity: 3337 cartons; Lot: Lot 179791, Mar 2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
American Health Packaging
Distributor
Nationwide USA and Puerto Rico
Lot
Lot 179791, Mar 2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Valsartan Tablets USP 160 mg, 100 Tablets (10 x 10) per Unit Dose Blisters, Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217 (Individual Dose NDC:60687-139-11, Carton NDC#: 60687-139-01) recalled?

Yes. FDA published recall D-1047-2019 on March 27, 2019. Reported hazard: CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.

What should I do if I have this product?

Voluntary: Firm initiated · Letter